Skip to main content
. 2023 Feb 15;11(2):444. doi: 10.3390/vaccines11020444

Figure 1.

Figure 1

Female patient (27 years old) with alopecia universalis post-AstraZeneca vaccine; (A.1) photographic record prior to vaccination; (A.2) alopecia universalis after COVID-19 vaccination. Female patient (51 years old) with telogen effluvium pos- AstraZeneca vaccination; (B.1) photographic record of telogen effluvium at medical consultation after administration of the vaccine; (B.2) photographic record of evolution after treatment (80% improvement). Male patient (34 years old) with telogen effluvium after AstraZeneca vaccine; (C.1) photographic record of telogen effluvium at medical consultation after administration of the vaccine; (C.2) photographic record of evolution after treatment (50% improvement). Male patient (40 years old) with telogen effluvium after AstraZeneca vaccine; (D.1) photographic record of telogen effluvium at medical consultation after administration of the vaccine; (D.2) photographic record of evolution after treatment (90% improvement). Male patient (59 years old) with alopecia universalis post-AstraZeneca vaccine; (E.1) personal photographic record prior to vaccine administration; (E.2) alopecia areata post-vaccination; (E.3) alopecia universalis after treatment.